Annarita Savi
Overview
Explore the profile of Annarita Savi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
di Gaeta E, Olivieri M, Savi A, Magnani P, Canevari C, Gusmini S, et al.
Radiol Med
. 2024 Dec;
PMID: 39707126
Purpose: Personalized treatment schemes are being systematically applied to ensure best treatment outcome in oncologic patients. This is true also for personalized dosimetry in transarterial radioembolization (TARE) in hepatocellular carcinoma...
2.
Ghezzo S, Neri I, Mapelli P, Savi A, Samanes Gajate A, Brembilla G, et al.
Bioengineering (Basel)
. 2023 Aug;
10(8).
PMID: 37627838
This study proposed a new workflow for co-registering prostate PET images from a dual-tracer PET/MRI study with histopathological images of resected prostate specimens. The method aims to establish an accurate...
3.
Presotto L, Bettinardi V, Bagnalasta M, Scifo P, Savi A, Vanoli E, et al.
J Digit Imaging
. 2022 Jan;
35(3):432-445.
PMID: 35091873
Deep learning (DL) strategies applied to magnetic resonance (MR) images in positron emission tomography (PET)/MR can provide synthetic attenuation correction (AC) maps, and consequently PET images, more accurate than segmentation...
4.
Mapelli P, Ghezzo S, Samanes Gajate A, Preza E, Brembilla G, Cucchiara V, et al.
Diagnostics (Basel)
. 2021 Nov;
11(11).
PMID: 34829417
The aim of the present study is to investigate the synergic role of Ga-PSMA PET/MRI and Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients...
5.
Ghezzo S, Bezzi C, Presotto L, Mapelli P, Bettinardi V, Savi A, et al.
Crit Rev Oncol Hematol
. 2021 Nov;
169:103544.
PMID: 34801699
We present the current clinical applications of radiomics in the context of prostate cancer (PCa) management. Several online databases for original articles using a combination of the following keywords: "(radiomic...
6.
Di Micco R, Santurro L, Gasparri M, Zuber V, Cisternino G, Baleri S, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298781
Axillary surgery in breast cancer (BC) is no longer a therapeutic procedure but has become a purely staging procedure. The progressive improvement in imaging techniques has paved the way to...
7.
Mapelli P, Bettinardi V, Fallanca F, Incerti E, Compierchio A, Rossetti F, et al.
Curr Radiopharm
. 2017 Nov;
11(1):50-57.
PMID: 29119942
Purpose: To assess the capability of 18F-FAZA PET/CT in identifying intratumoral hypoxic areas in early and locally advanced non-small cell lung cancer (NSCLC) patients and to compare 18FFAZA PET/CT with...
8.
Gallivanone F, Valente M, Savi A, Canevari C, Castiglioni I
Front Biosci (Landmark Ed)
. 2017 Apr;
22(10):1750-1759.
PMID: 28410143
The concept of targeted radionuclide therapy (TRT) relies on the use of injected nuclear medicine as treating agents, targeted at the cellular or molecular level. The growth of the interest...
9.
Savi A, Incerti E, Fallanca F, Bettinardi V, Rossetti F, Monterisi C, et al.
J Nucl Med
. 2017 Feb;
58(8):1224-1229.
PMID: 28209906
F-labeled fluoroazomycinarabinoside (F-FAZA) is a PET biomarker for noninvasive identification of regional tumor hypoxia. The aim of the present phase I study was to evaluate the biodistribution and dosimetry of...
10.
Zoccarato O, Marcassa C, Lizio D, Leva L, Lucignani G, Savi A, et al.
J Nucl Cardiol
. 2016 May;
24(5):1626-1636.
PMID: 27233252
Background: New technologies are available in MPI. Our aim was to evaluate their impact on the uniformity of normal myocardial uptake in the polar-map representation, over different count statistics, with...